China's NMPA approves Dova Pharma's Doptelet

30 April 2020

Dova Pharmaceuticals, which was acquired by Swedish Orphan Biovitrum (STO: SOBI) last year, today announced Doptelet (avatrombopag) has been granted approval from the China National Medical Products Administration (NMPA) for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure (ie, the CLD indication).

Mahmood Ladha, president and head of Dova, commented: "Receiving the approval for Doptelet from the China NMPA marks another significant milestone for Dova and our growing leadership in the global treatment of thrombocytopenia. Doptelet is the first treatment for this indication approved in China, offering patients a safe and effective orally-administered alternative to platelet transfusions for increasing platelet counts to the target level."

Clinical backing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK